

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity PRIMA BIOMED LIMITED (ASX:PRR)
ABN 90 009 237 889

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Mr Marc Voigt
Date of last notice	5 August 2015

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	N/A
Date of change	1 October 2015

+ See chapter 19 for defined terms.

For personal use only

Appendix 3Y
Change of Director's Interest Notice

<p>No. of securities held prior to change</p>	<p>1) Ordinary Fully Paid Shares</p> <table border="1" data-bbox="762 277 1342 423"> <thead> <tr> <th></th> <th>Shares</th> <th>Options</th> </tr> </thead> <tbody> <tr> <td>Direct</td> <td>7,536,666</td> <td>1,171,754</td> </tr> <tr> <td>Indirect</td> <td>-</td> <td>-</td> </tr> <tr> <td>Total</td> <td>7,536,666</td> <td>1,171,754</td> </tr> </tbody> </table> <p>2) American Depositary Receipts (ADR)</p> <table border="1" data-bbox="762 495 1342 640"> <thead> <tr> <th></th> <th>Shares</th> <th>Options</th> </tr> </thead> <tbody> <tr> <td>Direct</td> <td>150</td> <td>-</td> </tr> <tr> <td>Indirect</td> <td>-</td> <td>-</td> </tr> <tr> <td>Total</td> <td>150</td> <td>-</td> </tr> </tbody> </table> <p style="text-align: center;">1 ADR = 30 Ordinary Shares</p> <p>3) 4,068,627 STI Performance Rights and 12,254,902 LTI Performance Rights in accordance with shareholder approval obtained at 2014 AGM.</p> <p>4) 13,333,334 Performance Rights in accordance with shareholder approval obtained at the Extraordinary General Meeting on 31 July 2015.</p>		Shares	Options	Direct	7,536,666	1,171,754	Indirect	-	-	Total	7,536,666	1,171,754		Shares	Options	Direct	150	-	Indirect	-	-	Total	150	-
	Shares	Options																							
Direct	7,536,666	1,171,754																							
Indirect	-	-																							
Total	7,536,666	1,171,754																							
	Shares	Options																							
Direct	150	-																							
Indirect	-	-																							
Total	150	-																							
<p>Class</p>	<p>Ordinary Fully Paid Shares</p>																								
<p>Number acquired</p>	<p>1) Ordinary Fully Paid Shares</p> <table border="1" data-bbox="762 1117 1342 1296"> <thead> <tr> <th></th> <th>Shares</th> <th>Options</th> </tr> </thead> <tbody> <tr> <td>Direct</td> <td>4,068,627</td> <td>-</td> </tr> <tr> <td>Indirect</td> <td>-</td> <td>-</td> </tr> <tr> <td>Total</td> <td>4,068,627</td> <td>-</td> </tr> </tbody> </table>		Shares	Options	Direct	4,068,627	-	Indirect	-	-	Total	4,068,627	-												
	Shares	Options																							
Direct	4,068,627	-																							
Indirect	-	-																							
Total	4,068,627	-																							
<p>Number disposed</p>	<p>4,068,627 Performance Rights</p>																								
<p>Value/Consideration <small>Note: If consideration is non-cash, provide details and estimated valuation</small></p>	<p>Nil</p> <p>The Performance Rights were issued pursuant to the Company's Executive Incentive Plan in accordance with shareholder's approval obtained at the Annual General Meeting on 14 November 2014. No amount is payable upon exercise of the Performance Rights for shares after vesting.</p>																								

+ See chapter 19 for defined terms.

For personal use only

Appendix 3Y
Change of Director's Interest Notice

No. of securities held after change	1) Ordinary Fully Paid Shares	
	Shares	Options
	Direct	11,605,293
	Indirect	-
	Total	11,605,293
	2) American Depositary Receipts (ADR)	
	Shares	Options
	Direct	150
	Indirect	-
	Total	150
	3) 12,254,902 LTI Performance Rights in accordance with shareholder approval obtained at 2014 AGM.	
	4) 13,333,334 Performance Rights in accordance with shareholder approval obtained at the Extraordinary General Meeting on 31 July 2015.	
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	1) Acquiring 4,068,627 shares upon exercise of the Short Term Incentive performance rights. One ordinary fully paid share was acquired for each Performance Right that vested.	

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	
Name of registered holder (if issued securities)	
Date of change	
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	
Interest acquired	
Interest disposed	

+ See chapter 19 for defined terms.

For personal use only

Appendix 3Y
Change of Director's Interest Notice

Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	
Interest after change	

Part 3 – +Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	
If prior written clearance was provided, on what date was this provided?	

For personal use only

+ See chapter 19 for defined terms.